Tandem Diabetes Care, Inc. TNDM · NASDAQ
$17.15 +4.89% (+$0.80)
Summary
29 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
- Revenue growth is slowing: 8.2% a year over the last 3 years against 15% over 5 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 8.2% a year. For the next fiscal year analysts expect revenue to grow by 5.7%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $63.3M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 24
- Hold 15
- Sell 0
Today's price within the analysts' price targets
The average target of $30.17 is 76% above today's price. 62% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Supplies and Other 54%
- Pump 46%
By region
- UNITED STATES 70%
- Non-US 30%
Supplies and Other brings in 54% of revenue.
Segments in detail